Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. (2023)

First Author: Madhi SA
Attributed to:  nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19 funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(22)00596-5

PubMed Identifier: 36273491

Publication URI: http://europepmc.org/abstract/MED/36273491

Type: Journal Article/Review

Volume: 23

Parent Publication: The Lancet. Infectious diseases

Issue: 3

ISSN: 1473-3099